Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Certolizumab Pegol
Therapeutic Area : Gastroenterology
Study Phase : Preclinical
Sponsor : Alvotech
Deal Size : $10.1 million
Deal Type : Acquisition
Alvotech Acquires Xbrane’s R&D, Strengthening Biosimilars Leadership Globally
Details : Through the acquisition, Alvotech leverages R&D operations and a biosimilar candidate of Xbrane XB003 (certolizumab pegol). It is being evluated for treating crohn disease.
Product Name : XB003
Product Type : Antibody-drug Conjugate
Upfront Cash : $10.1 million
March 20, 2025
Lead Product(s) : Certolizumab Pegol
Therapeutic Area : Gastroenterology
Highest Development Status : Preclinical
Sponsor : Alvotech
Deal Size : $10.1 million
Deal Type : Acquisition
Lead Product(s) : Certolizumab Pegol
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CIMZIA (certolizumab pegol) is the only Fc-free, PEGylated anti-TNF (Tumor Necrosis Factor). CIMZIA has a high affinity for human TNF-alpha, selectively neutralizing the pathophysiological effects of TNF-alpha.
Product Name : Cimzia
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
August 11, 2022
Lead Product(s) : Certolizumab Pegol
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Certolizumab Pegol
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Biogen
Deal Size : $88.0 million
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, Biogen will gain exclusive global regulatory, manufacturing, and commercial rights to Xcimzaneâ„¢ and will be the Marketing Authorization Holder.
Product Name : Xcimzane
Product Type : Antibody-drug Conjugate
Upfront Cash : $8.0 million
July 02, 2022
Lead Product(s) : Certolizumab Pegol
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Biogen
Deal Size : $88.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Certolizumab Pegol
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The findings confirm that patients with axSpA who achieve sustained remission benefit from continued certolizumab pegol treatment, either with the full or reduced maintenance dose - over treatment withdrawal.
Product Name : Cimzia
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
January 06, 2021
Lead Product(s) : Certolizumab Pegol
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Certolizumab Pegol
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : UCB Pharma S.A
Deal Size : Undisclosed
Deal Type : Agreement
Details : The outcomes-based agreement for the CIMZIA lyophilized powder healthcare professional administered formulation applies to all commercial members in Highmark's national and core health insurance markets in Pennsylvania, West Virginia, and Delaware.
Product Name : Cimzia
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
August 18, 2020
Lead Product(s) : Certolizumab Pegol
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : UCB Pharma S.A
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Certolizumab Pegol
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : UCB Pharma S.A
Deal Size : Undisclosed
Deal Type : Agreement
Details : Ferring joins with UCB to promote CIMZIA prefilled syringe for Crohn’s disease in the United States. Co-promotion strengthens commitment to patients living with Crohn’s disease by reaching more gastroenterologists while also continuing patient suppor...
Product Name : Cimzia
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
August 07, 2020
Lead Product(s) : Certolizumab Pegol
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : UCB Pharma S.A
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Certolizumab Pegol
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : EMA has approved a label extension for CIMZIA for use in adult patients with axial spondyloarthritis (axSpA) at a reduced maintenance dose of 200 mg every four weeks, once sustained remission is achieved after one year of CIMZIA 200 mg every two weeks o...
Product Name : Cimzia
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
May 08, 2020
Lead Product(s) : Certolizumab Pegol
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Certolizumab Pegol
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
UCB Shares Breadth of Innovative New Data from Rheumatology Portfolio for EULAR 2020 E-Congress
Details : Four-year results from the RAPID-axSpA study of CIMZIA[®] (certolizumab pegol) highlight the importance of early, effective and long-term treatment targeting inflammation.
Product Name : Cimzia
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
April 06, 2020
Lead Product(s) : Certolizumab Pegol
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable